skip to main content

CM3.B6

CM3.B6

Catalogue No.

11060101

Cell Line Name

CM3.B6

Cell Line Description

Human B-lymphocyte cell line, immortalized with Epstein-Barr Virus (EBV), derived from a patient with chronic Hepatitis C (HCV type 1). Cell line produces human monoclonal antibody specific for non-structural protein NS3 (helicase domain). This antibody binds to a major conformational epitiope located at the carboxyl-terminal end of the NS3 region that is recognised by approximately ~90% from HCV-infected patients. CM3.B6 can be used in immunochemistry, HCV protein purification and HCV typing.CM3.B6 and B12.F8 (ECACC Catalogue number 11060102) were derived from the same patient as confirmed by STR profiling.

General Info

Species

Human

Release Conditions

Restricted – all customers must complete the specific depositor MTA.

Characteristics

Tissue of Origin

Blood

Morphology

Small rounded cells

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 11,12
D5S818: 11,13
D7S820: 8,11
D13S317: 9,11
D16S539: 11,12
TH01: 6
TPOX: 9,11
vWA: 14,16

Disease

None Stated

Culture Conditions

Cell Type

Lymphoblastoid

Subculture Routine

Maintain cultures between 3-9 x 10⁵/ml. 5% CO₂; 37°C. Media change every two days. Saturation density 1.1 x 10⁶/ml

Culture Medium

RPMI-1640 + 2mM L-Glutamine + 1% Non-Essential Amino Acids (NEAA) + 1% Sodium Pyruvate (NaP) + 10% Foetal Bovine Serum (FBS) + 20U/ml Interlukin-6 (IL-6).

Growth Mode

Suspension

Additional Info

Depositor

Mario U Mondelli, MD PhD FRCP, Professor of Infectious Diseases, University of Pavia, Director, Research Laboratories and Hepatology Centre, Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Country of Origin

Italy

GMO Status

Genetically Modified Organism Class 1 (GMO1)

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Mondelli MU, Cerino A, Boender P, Oudshoorn P, Middeldorp J, Fipaldini C, La Monica N, Habets W 1994 Significance of the immune response to a major, conformational B-cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody. J Virol. 68(8):4829-36 PMID: 7518528.

Bibliography

Cerino A, Mondelli MU 1991 Identification of an immunodominant B cell epitope on the hepatitis C virus nonstructural region defined by human monoclonal antibodies.J Immunol. 147(8):2692-6 PMID: 1717573. Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU 1993 A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol. 151(12):7005-15 PMID: 7505020.

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: CM3.B6 (ECACC 11060101).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.